Clinical Trials Logo

Ependymoblastoma clinical trials

View clinical trials related to Ependymoblastoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03581240 Available - Neuroblastoma Clinical Trials

An Intermediate Expanded Use Trial of DFMO

Start date: n/a
Phase:
Study type: Expanded Access

To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.

NCT ID: NCT01082926 Completed - Glioblastoma Clinical Trials

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Start date: May 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Donor T cells that are treated in the laboratory may be effective treatment for malignant glioma. Aldesleukin may stimulate the white blood cells to kill tumor cells. Combining different types of biological therapies may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best way to give therapeutic donor lymphocytes together with aldesleukin in treating patients with stage III or stage IV malignant glioma.